RxDoctor Payments Data

Erica Bustillo

Family · New Orleans, LANPI 1033794052

Payments from drug & device makers

$2,794in general payments, 2019–2025

Across 145 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$479
  • Alnylam Pharmaceuticals Inc.$394
  • AstraZeneca$236
  • Irhythm Technologies, Inc.$203
  • Novo Nordisk$188
  • Johnson & Johnson$185
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,794 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,956
Medicare patients
183
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$110,199
EntrestoSacubitril/Valsartan59$89,519
JardianceEmpagliflozin38$59,000
Repatha SureclickEvolocumab18$15,425
Praluent PenAlirocumab19$15,076
XareltoRivaroxaban12$13,743
Metoprolol Succinate155$1,517
Irbesartan79$1,094
Rosuvastatin Calcium102$1,022
Ezetimibe50$983
Nebivolol Hcl23$953
Pravastatin Sodium40$837
Valsartan30$633
Nifedipine ErNifedipine32$619
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$110,19994 claims
NovartisEntresto$479$89,51959 claims
Boehringer IngelheimJardiance$68$59,00038 claims
Johnson & JohnsonXarelto$185$13,74312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →